151 related articles for article (PubMed ID: 38096164)
21. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
22. Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients.
Yuan J; Liu H; Hu S; Miranda RN; Xu X; Bayerl MG; Artymiuk CJ; Berg H; King RL; Shi M; He R; Viswanatha D; Medeiros LJ; McPhail ED
Hum Pathol; 2023 Nov; 141():22-29. PubMed ID: 37634651
[TBL] [Abstract][Full Text] [Related]
23. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.
Saieg MA; Geddie WR; Boerner SL; Bailey D; Crump M; da Cunha Santos G
Cancer Cytopathol; 2013 Jul; 121(7):377-86. PubMed ID: 23361872
[TBL] [Abstract][Full Text] [Related]
24. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
Alcaide M; Yu S; Bushell K; Fornika D; Nielsen JS; Nelson BH; Mann KK; Assouline S; Johnson NA; Morin RD
Clin Chem; 2016 Sep; 62(9):1238-47. PubMed ID: 27440511
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
26. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
Burkhard R; Bhagat G; Cogliatti SB; Rossi D; Gaidano G; Pasqualucci L; Novak U
Hematol Oncol; 2015 Mar; 33(1):23-30. PubMed ID: 24496723
[TBL] [Abstract][Full Text] [Related]
27. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
28. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
[TBL] [Abstract][Full Text] [Related]
29. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.
Lopez-Rios F; Angulo B; Gomez B; Mair D; Martinez R; Conde E; Shieh F; Vaks J; Langland R; Lawrence HJ; de Castro DG
PLoS One; 2013; 8(1):e53733. PubMed ID: 23326492
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.
Nagy Á; Bátai B; Balogh A; Illés S; Mikala G; Nagy N; Kiss L; Kotmayer L; Matolcsy A; Alpár D; Masszi T; Masszi A; Bödör C
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32668764
[TBL] [Abstract][Full Text] [Related]
31. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
32. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.
Ma H; Luo X; Zhou P; He N; Zhou J; Liu M; Xie W
J Clin Lab Anal; 2021 Mar; 35(3):e23693. PubMed ID: 33389794
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Bisserier M; Wajapeyee N
Blood; 2018 May; 131(19):2125-2137. PubMed ID: 29572378
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma.
Pon JR; Marra MA
Blood; 2016 Jan; 127(2):181-6. PubMed ID: 26447189
[TBL] [Abstract][Full Text] [Related]
35. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL; van Eijk R; Böhringer S; van Wezel T; Raghoo R; Ruano D; Jansen PM; Briaire-de Bruijn I; de Groot FA; Kleiverda K; Te Boome L; Terpstra V; Levenga H; Nicolae A; Posthuma EFM; Focke-Snieders I; Hardi L; den Hartog WCE; Bohmer LH; Hogendoorn PCW; van den Berg A; Diepstra A; Nijland M; Lugtenburg PJ; Kersten MJ; Pals ST; Veelken H; Bovée JVMG; Cleven AHG; Vermaat JSP
Blood Adv; 2021 Oct; 5(19):3760-3775. PubMed ID: 34478526
[TBL] [Abstract][Full Text] [Related]
36. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
37. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN
Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047
[TBL] [Abstract][Full Text] [Related]
38. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
39. Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.
Brown RE; Zhang S; Wang XI
Ann Clin Lab Sci; 2022 Jan; 52(1):27-32. PubMed ID: 35181615
[TBL] [Abstract][Full Text] [Related]
40. Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.
Tong KI; Yoon S; Isaev K; Bakhtiari M; Lackraj T; He MY; Joynt J; Silva A; Xu MC; Privé GG; He HH; Tiedemann RE; Chavez EA; Chong LC; Boyle M; Scott DW; Steidl C; Kridel R
Clin Cancer Res; 2021 Oct; 27(19):5401-5414. PubMed ID: 34168051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
